CCRP practice question 25 of 25
Which of the following is one of the responsibilities of an investigator who is NOT a sponsor?
Full set: 130 questionsDomain Study Management/Conduct of the Study
An investigator's responsibilities, as distinct from a sponsor's, are focused on the conduct of the trial at their specific site. According to both U.S. Food and Drug Administration (FDA) regulations and International Council for Harmonisation (ICH) Good Clinical Practice (GCP) guidelines, the investigator is directly responsible for maintaining control over the investigational product. This includes ensuring proper storage, dispensing only to eligible subjects according to the protocol, and maintaining accurate accountability records for the product received, used, and returned. The other options listed are responsibilities of the study sponsor.
A. Reporting serious adverse events to the applicable regulatory agency is a sponsor's responsibility. The investigator reports SAEs to the sponsor and the Institutional Review Board (IRB).
B. Ensuring proper monitoring of an investigation at all investigational sites is a core function of the sponsor, who must select monitors and ensure trial oversight across all locations.
C. Ensuring that all participating investigators are promptly informed of significant new adverse events is the sponsor's duty, as they aggregate safety data from all sites.
1. U.S. Food and Drug Administration, Code of Federal Regulations Title 21, Part 312.61, "Control of the investigational drug." This regulation explicitly states, "An investigator is required to administer the drug only to subjects under the investigator's personal supervision or under the supervision of a subinvestigator responsible to the investigator. The investigator shall not supply the investigational drug to any person not authorized under this part to receive it."
2. International Council for Harmonisation (ICH) Harmonised Tripartite Guideline, "Guideline for Good Clinical Practice E6(R2)," Section 4.6, "Investigational Product(s)." This section details the investigator's responsibility for investigational product accountability at the trial site, including records of delivery, inventory, use, and disposition.
3. U.S. Food and Drug Administration, Code of Federal Regulations Title 21, Part 312.50, "General responsibilities of sponsors." This section outlines the sponsor's role in selecting qualified investigators, ensuring proper monitoring (312.56), and ensuring FDA and all participating investigators are informed of significant new adverse events (312.55(b)).
4. U.S. Food and Drug Administration, Code of Federal Regulations Title 21, Part 312.32, "IND safety reporting." This regulation specifies that the sponsor must notify the FDA and all participating investigators in an IND safety report of potential serious risks. The investigator's duty is to report adverse events to the sponsor.
5. Johns Hopkins University, "Investigator Responsibilities - FAQs." The university's guidance for researchers clarifies roles, stating, "The PI [Principal Investigator] is responsible for ensuring that the storage, dispensing, and use of the investigational agent is controlled and that accurate accountability records are maintained." It distinguishes this from sponsor duties like multi-site monitoring and regulatory reporting. (Available on the Johns Hopkins Medicine institutional website under research compliance).
Keep practicing
Take the free CCRP practice test
Ten exam-style questions with answers and explanations, plus the exam facts and study guides.
More questions
Other CCRP practice questions
- Question 1The study coordinator for a new Phase III vaccine study is preparing documents for IRB/IE…
- Question 2In a completed multi-site Phase I drug study using remote EDC, who ensures the system com…
- Question 3Which of the following is an example of an additional protection required when conducting…
- Question 4A clinical investigator is planning to conduct a quality of life medical device study in …
- Question 5In accordance with the ICH GCP Guideline, prior to initiating a trial, which of the follo…
- Question 6According to the CFR and the ICH GCP Guideline, which of the following must be submitted …
